Diabetes mellitus is a chronic, lifelong condition that affects your body's ability to use the energy found in food. There are three major types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes.
All types of diabetes mellitus have something in common. Normally, your body breaks down the sugars and carbohydrates you eat into a special sugar called glucose. Glucose fuels the cells in your body. But the cells need insulin, a hormone, in your bloodstream in order to take in the glucose and use it for energy. With diabetes mellitus, either your body doesn't make enough insulin, it can't use the insulin it does produce, or a combination of both.
Since the cells can't take in the glucose, it builds up in your blood. High levels of blood glucose can damage the tiny blood vessels in your kidneys, heart, eyes, or nervous system. That's why diabetes -- especially if left untreated -- can eventually cause heart disease, stroke, kidney disease, blindness, and nerve damage to nerves in the feet.
Improvements have been seen in the following symptoms after treatment:
Better glycemic control
Significant decreases in insulin requirement
Higher energy levels
Which Kinds of cells are used in Diabetes Mellitus and how are they obtained?
Adult stem cells are obtained from itc bank from donor tissue or autologous transplant, which is harvested from the patient’s own adipose tissue and it takes 21 days to culture, differentiate and administer the adult stem cells to the patient.
How are Mesenchymal Stem Cells (MSC) administered in Diabetes Mellitus?
A typical treatment is as following; stem cells are administered by a license physician.
Medical evaluation, blood testing,
1 intravenous injections of adipose tissue-derived mesenchymal stem cells with Vit. C, Eicosanoids and Amnoaciids(day 1)
Hyperbaric Chamber(day 2)
1 intravenous injections of adipose tissue-derived mesenchymal stem cells with Vit. C, Eicosanoids and Aminoacids(day 3)
Couri, C. & Voltarelli, J. (2008). Autologous stem cell transplantation for early type 1 diabetes mellitus. Autoimmunity, 41(8), 666-672.
Couri, C. (2009). C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA, 301(15), 1573. http://dx.doi.org/10.1001/jama.2009.470
Voltarelli, J., Couri, C., Stracieri, A., Oliveira, M., Moraes, D., & Pieroni, F. et al. (2007). Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA, 297(14), 1568. http://dx.doi.org/10.1001/jama.297.14.1568
Zhang, X., Ye, L., Hu, J., Tang, W., Liu, R., & Yang, M. et al. (2012). Acute Response of Peripheral Blood Cell to Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetic Patient. Plos ONE, 7(2), e31887. http://dx.doi.org/10.1371/journal.pone.0031887